Thomas W M, Hardcastle J D, Jackson J, Pye G
Department of Surgery, University Hospital, Nottingham, UK.
Br J Cancer. 1992 Apr;65(4):618-20. doi: 10.1038/bjc.1992.125.
An established chemical faecal occult blood test (Haemoccult prepared without rehydration) has been compared with a new immunological test (Hemeselect) in patients referred for investigation of lower gastro-intestinal symptoms. Hemeselect was shown to have a higher sensitivity for colorectal carcinoma (94.0% compared with 58.0%), the greatest difference in sensitivity between the two tests being for rectal cancers. Similarly Hemeselect was more sensitive than Haemoccult for colorectal adenomas (66.6% vs 33.3%), and for inflammatory bowel disease (88.9% vs 33.3%). However the enhanced sensitivity of Hemeselect for colorectal neoplasia and inflammatory bowel disease was accompanied by a significant increase in the overall rate of positive reactions (32.8% of patients had a positive Hemeselect reaction compared with 14.8% who had a positive Haemoccult test), and a reduction in specificity (84.1% for Hemeselect vs 96.0% for Haemoccult). Hemeselect is a more sensitive indicator of colorectal neoplasia in symptomatic subjects, trials of its use as a screening test for asymptomatic neoplasia appear justified.
在因下消化道症状前来接受检查的患者中,已将一种成熟的化学粪便潜血试验(未复水制备的隐血便试剂)与一种新的免疫试验(Hemeselect)进行了比较。结果显示,Hemeselect对结直肠癌的敏感性更高(94.0%,而化学粪便潜血试验为58.0%),两种试验之间敏感性差异最大的是直肠癌。同样,Hemeselect对大肠腺瘤(66.6%对33.3%)和炎症性肠病(88.9%对33.3%)的敏感性也高于化学粪便潜血试验。然而,Hemeselect对结直肠肿瘤和炎症性肠病敏感性的提高伴随着阳性反应总发生率的显著增加(32.8%的患者Hemeselect反应呈阳性,而化学粪便潜血试验呈阳性的患者为14.8%),以及特异性的降低(Hemeselect为84.1%,化学粪便潜血试验为96.0%)。Hemeselect是有症状受试者结直肠肿瘤更敏感的指标,将其用作无症状肿瘤筛查试验的相关试验似乎是合理的。